Aptuit

Evotec to acquire Aptuit

Tuesday, August 1, 2017

Evotec and Aptuit announced that they have entered into a definitive agreement under which Evotec will acquire Aptuit for $300 million. This transaction will strengthen Evotec’s position as the leading global player in the external innovation marketplace. As a partner research organization for integrated outsourced drug discovery and development solutions, Aptuit offers highly synergistic scientific expertise across drug discovery, pre-clinical testing and both drug substance and drug product manufacturing to its Biopharma partners. The acquisition will add considerable business opportunities to further accelerate Evotec’s long-term strategy to be the industry partner of choice for external innovation.

[Read More]

AMRI to acquire Aptuit drug development, aseptic manufacturing businesses

Friday, January 9, 2015

Albany Molecular Research (AMRI), a global contract research and manufacturing organization, has acquired the outstanding equity interests of Aptuit‘s Glasgow, U.K., business and has entered into a definitive agreement to acquire Aptuit’s SSCI/West Lafayette, Ind., business, for a total of $60 million, expanding AMRI’s drug product development and aseptic clinical manufacturing capabilities.

[Read More]

Aptuit names Jonathan Goldman as CEO

Thursday, December 5, 2013

Aptuit has appointed Jonathan Goldman, M.D., as CEO. Goldman will focus on the growth of Aptuit as a provider of outsourced services in the early development space by establishing new partnerships with clients and pursuing strategic acquisitions. He joins the company after success at Icon Clinical Research, a global CRO specializing in the provision of clinical and other solutions that support phase I-IV clinical studies.

[Read More]